N-[(2R,3S)-2-(2,5-Difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]carbamic acid 1,1-dimethylethyl ester

We are N-[(2R,3S)-2-(2,5-Difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]carbamic acid 1,1-dimethylethyl ester CAS:951127-25-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  N-[(2R,3S)-2-(2,5-Difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]carbamic acid 1,1-dimethylethyl ester
CAS.NO:  951127-25-6
Synonyms:MK-3102 intermediate I
Omarigliptin intermediate I
tert-butyl [(2R,3S)-5-oxo-2-(2,5-difluorophenyl)tetradihydro-2H-pyran-3-yl]carbamate
tert-butyl [(2R,3S)-5-oxo-2-(2,5-difluorophenyl)tetrahydro-2H-pyran-3-yl]carbamate
tert-butyl [(2R,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pvran-3 yl]carbamate

Molecular Formula: C16H19F2NO4
Molecular Weight: 327.32300

Physical and Chemical Properties:
Density:1.3±0.1 g/cm3
Boiling point: 433.4±45.0 °C at 760 mmHg
Melting point: /
Flash point: 215.9±28.7 °C
Refractive index: 1.516

Specification:
Appearance:  White  powder
Purity: >99％
Water:0.5% Max.

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a well-closed container at low temperature, keep away from moisture, heat and light.
Application:Intermediates of Oralliptin CAS:1226781-44-7 .

Related News: High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies.Tretinoin CAS:302-79-4 The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform.1-[(1,3,4-trimethyl-4,5-dihydroimidazol-1-ium-2-yl)oxy]pyrrolidine-2,5-dione,tetrafluoroborate CAS:443305-34-8 Many domestic raw material pharmaceutical and intermediate manufacturing companies with strong capital and talent reserves and advanced technology and processes have developed in the country, and the competitiveness of market participants has continued to increase.benzyl (4S)-2,5-dioxo-4-propan-2-yl-1,3-oxazolidine-3-carboxylate CAS:158257-41-1 Many domestic raw material pharmaceutical and intermediate manufacturing companies with strong capital and talent reserves and advanced technology and processes have developed in the country, and the competitiveness of market participants has continued to increase.A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.